Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates - Fonseca, Ana Rita da; Justino, Caio Cesar; Molla, Vinicius Campos de; Yamakawa, Patricia Eiko; Rabelo, Iara Baldim; Arnold, Louise; Kelly, Richard; Grif, Morag; Munir, Talha; Velloso, Elvira Deolinda Rodrigues Pereira (Blood advances, 2025)